"The solid tumor barrier no longer represents a monolithic obstacle. Rather, it represents a collection of discrete, definable engineering challenges."
BUFFALO, NY — August 11, 2026 — A new review was published in Volume 13 of Oncoscience on July 29, 2026, titled " Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation ."
The review was led by first and corresponding author Samuel Obiosa Onyekweli from the Department of Internal Medicine, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria .
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of several blood cancers, but its effectiveness against solid tumors has remained limited. A meta-analysis cited in the review estimated a pooled objective response rate of approximately 9% for CAR-T therapy in solid malignancies, highlighting the large efficacy gap between solid and hematologic cancers.
The authors explain that this gap is driven by several interacting barriers rather than a single obstacle. CAR-T cells must penetrate dense tumor stroma and abnormal vasculature, survive nutrient depletion and hypoxia, overcome immunosuppressive signals, recognize heterogeneous tumor antigens, and resist progressive exhaustion. The review therefore frames the solid tumor microenvironment as a collection of distinct engineering problems that can potentially be addressed through coordinated design.
One of the review's central themes is a shift from maximizing T-cell potency toward building cellular resilience. Earlier CAR-T approaches largely focused on stronger activation and costimulatory signaling, whereas newer strategies aim to protect engineered T cells from the hostile conditions encountered inside solid tumors through metabolic armoring, epigenetic protection, improved trafficking, and resistance to suppressive signaling.
T-cell exhaustion is a major part of this challenge. Chronic stimulation can progressively lock CAR-T cells into dysfunctional transcriptional states. The review discusses strategies including c-Jun overexpression to restore AP-1-dependent transcription, DNMT3A disruption to interfere with epigenetic exhaustion programs, cytokine armoring with IL-10, IL-15, IL-18, or IL-21 to support cellular fitness, and dominant-negative receptors such as dnTGF-βRII to shield CAR-T cells from immunosuppressive signaling.
Other engineering approaches address tumor access and targeting specificity. Chemokine receptors such as CCR2b can improve tumor trafficking, while hypoxia-responsive CARs exploit low-oxygen conditions to restrict activity toward the tumor environment. Synthetic biology platforms, including synNotch AND-gates, Tmod NOT-gates, and drug-controlled CAR systems, add further control by requiring specific molecular conditions before engineered T cells become fully active.
The authors argue that recent clinical developments suggest that some of these engineering principles are beginning to translate into meaningful outcomes. In H3K27M-mutated diffuse midline glioma, intracerebroventricular GD2-targeted CAR-T therapy produced major tumor reductions, including a complete response sustained beyond 30 months.
In advanced gastric cancer, CLDN18.2-targeted satricabtagene autoleucel, or satri-cel, demonstrated superiority over physician's choice in a randomized Phase 2 trial, with a progression-free survival hazard ratio of 0.37 and an overall survival hazard ratio of 0.69. The review describes this as the first evidence of randomized CAR-T superiority over standard treatment in a solid malignancy.
Another notable example comes from hepatocellular carcinoma. GPC3-targeting C-CAR031 incorporates a dominant-negative TGF-β receptor to protect CAR-T cells from immunosuppressive signaling and achieved reported objective response rates of approximately 50–57%. However, the authors emphasize that these efficacy results currently derive from conference abstracts and await full peer-reviewed publication.
Beyond engineering the CAR-T cell itself, the review expands the therapeutic framework to the broader biological environment of the patient. Factors such as the gut microbiome, conditioning regimen, manufacturing duration, T-cell phenotype at infusion, and systemic neuroendocrine signaling may also influence CAR-T persistence and fitness. The authors argue that successful solid-tumor CAR-T therapy may therefore require optimization of the engineered cell, the tumor microenvironment, and the patient's broader physiological context.
Manufacturing is another major frontier. The review discusses next-day manufacturing approaches and emerging platforms that could generate CAR-T cells directly inside the patient using targeted lipid nanoparticles or receptor-targeted lentiviral particles. These technologies could eventually reduce manufacturing complexity and broaden access, although their regulatory and clinical pathways are still being defined.
"The path forward requires not merely applying hematologic paradigms to solid tumors, but fundamentally reconceptualizing the T cell as a drug product that must be delivered to the right compartment, armored against suppression, and integrated into a holistic therapeutic system that includes manufacturing optimization, microbiome stewardship, systemic physiological context, and rational combination strategies."
To organize these advances, the authors propose a four-tier framework for future solid-tumor CAR-T development. The first tier focuses on delivery, including locoregional administration for difficult-to-access tumors. The second emphasizes resilience, using armoring strategies to protect CAR-T cells from immunosuppressive environments. The third focuses on logic, using advanced targeting circuits to improve specificity. The fourth expands the concept to the entire system, incorporating factors such as the microbiome, conditioning, manufacturing, T-cell phenotype, and systemic physiology.
Despite recent progress, the authors emphasize that major questions remain unresolved. Long-term genomic stability after multiplex gene editing has not been established, sustained cytokine armoring introduces potential safety concerns, and increasingly complex CAR-T constructs create manufacturing and regulatory challenges. Biomarker-guided selection of specific engineering strategies also remains an aspirational approach that will require prospective clinical validation.
Overall, the review presents solid-tumor CAR-T therapy as moving from a strategy centered mainly on increasing T-cell potency toward one built around integrated, resilience-based engineering. By treating trafficking, metabolic stress, immune suppression, antigen heterogeneity, and epigenetic exhaustion as distinct but interconnected challenges, the authors outline a more systematic path toward next-generation CAR-T therapies. Recent clinical results are encouraging, but larger studies, longer follow-up, and rigorous validation will be needed to determine which strategies can produce durable benefits across different solid tumors.
DOI: https://doi.org/10.18632/oncoscience.666
